CoChat
Cited by 172

The DOI matches its Crossref record.

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer

Rochlitz, Christoph, Figlin, Robert, Squiban, Patrick, Salzberg, Marc, Pless, Miklos, Herrmann, Richard, Tartour, Eric, Zhao, Yongxiang, Bizouarne, Nadine, Baudin, Martine, Acres, Bruce · 2003 · The Journal of Gene Medicine

Abstract

Background: The MUC1 protein is a highly glycosylated mucin normally found at the apical surface of mucin‐secreting epithelial cells in many types of tissues. MUC1 is expressed, but heavily underglycosylated, in different human tumors. TG4010 is a viral suspension of a recombinant vaccinia vector (MVA) containing DNA sequences coding for the human MUC1 antigen and interleukin‐2 (IL‐2). This product was developed for use as a vaccine in cancer patients whose tumors express the MUC1 antigen. The objective of the present study was to determine the safety of the product and to define the dose of TG4010 to be used in further clinical trials. Materials and methods: Thirteen patients with different solid tumors were treated by repeated intramuscular injection with increasing doses of TG4010 in two separate phase I studies, one in Europe (Basel—CR) and one in the United States (UCLA—RF): a total of 6 patients were treated at a dose of 5 × 10 6 pfu, 3 patients at 5 × 10 7 pfu, and 4 patients at 10 8 pfu. Safety, efficacy, and different immunological tests were the endpoints of the study. Results: Tolerance of TG4010 was excellent, and side effects mainly consisted of injection site pain and influenza‐like symptoms. There was no apparent detrimental effect of repeated injections of the vaccinia virus. Four of thirteen evaluable patients showed stabilization of their disease for 6 to 9 months. One lung cancer patient who was initially progressing after the first injections later showed a marked decrease in the size of his metastases that lasted for 14 months. Some T cell proliferative immune responses were seen in five patients. Conclusions: The administration of TG4010 was generally well tolerated in patients with metastatic tumors, and transient disease stabilization was observed in several patients, warranting further clinical studies with the product. Copyright © 2003 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jgm.397

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 172

Metadata

Authors
Rochlitz, C., Figlin, R., Squiban, P., Salzberg, M., Pless, M., Herrmann, R., Tartour, E., Zhao, Y., Bizouarne, N., Baudin, M., & Acres, B.
Venue
The Journal of Gene Medicine
Publisher
Wiley
Published
2003-03-17
Volume
5
Issue
8
Pages
690-699
ISSN
  • 1099-498X (ISSN-L)
  • 1521-2254
OpenAlex
W1989332140
Cited by
172
References
0
FWCI
3.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer. https://app.cochat.ai/papers/10.1002/jgm.397
The paper
Rochlitz, C., Figlin, R., Squiban, P., Salzberg, M., Pless, M., Herrmann, R., Tartour, E., Zhao, Y., Bizouarne, N., Baudin, M., & Acres, B. (2003). Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.397

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.